Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Travere Therapeutics (TVTX) stock in plain English

Free brief · no signupStart here
TVTXPublished Nov 19, 2026
Travere Therapeutics Inc
Healthcare · Biotechnology
Sells prescription medicines including Filspari for rare kidney diseases and Thiola for cystinuria.
Assets:
Filspari drugApproved treatment for reducing proteinuria in primary IgA nephropathy.
San Diego headquartersPrimary operational base housing research, clinical development, and corporate management.
Specialized sales forceCommercial team dedicated to engaging nephrologists across the United States.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

43
OPS ScoreOperating finances
Latest quote
-3.86%$48.30
$4.64B
n/a (loss)
$651.18M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 19, 2026Quotes updated Nov 20, 04:00 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was TVTX. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Travere Therapeutics (TVTX) do?

Travere Therapeutics Inc (TVTX) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Sells prescription medicines including Filspari for rare kidney diseases and Thiola for cystinuria. Develops and commercializes specialized therapies targeting rare kidney and metabolic diseases. It is worth $4.64B on the market and sold $651.18M over the last year.

Market cap
$4.64B
P/E ratio
None (reported a loss)
Annual sales
$651.18M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 19, 2026

Brands and businesses behind TVTX

  • Filspari: Generates revenue by selling oral prescription tablets to treat kidney damage from primary IgA nephropathy.
  • Thiola EC: Earns revenue selling delayed release tablets to prevent cystine stone formation in cystinuria patients.

TVTX’s flags, in plain English

Each flag is a number from Travere Therapeutics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 19, 2026.

Wide Gross Margin

Gross margin of 90.4% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Stupid Cash

Can pay this year's bills 3 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Still Climbing

Sales up 19.9% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Debt Is Driving

Heavy debt, 2729% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.

2 more risk notes open with the free trial. Try it free for 7 days.

Questions about TVTX

How big is Travere Therapeutics?

Travere Therapeutics’ market cap is $4.64B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $651.18M: what customers paid the company over the last year, before any costs.

What is TVTX’s P/E ratio?

TVTX has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with TVTX?

The business depends heavily on commercial adoption of Filspari while operating with persistent yearly net losses. That is one risk on Travere Therapeutics’ card. Its first risk flag is Debt Is Driving, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Travere Therapeutics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. TVTX’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card